Eugenics Medi Sciences Private Limited

Provides healthcare solutions through a range of products including creams, tablets, gel, syrup, and power.

2006 | Lucknow, Uttar Pradesh (India) | Active
Last Updated: July 04, 2024

Eugenics Medi Sciences Profile

Key Indicators

  • Authorised Capital ₹ 2.50 Cr
  • Paid Up Capital ₹ 2.40 Cr
  • Company Age 18 Year, 10 Months
  • Last Filing with ROC 31 Mar 2023
  • Open Charges ₹ 114.56 Cr
  • Satisfied Charges ₹ 72.50 Cr
  • Revenue Growth 34.77%
  • Profit Growth 50.07%
  • Ebitda 44.38%
  • Net Worth 25.87%
  • Total Assets 59.92%

About Eugenics Medi Sciences

Eugenics Medi Sciences Private Limited (EMSPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 24 April 2006 and has a history of 18 years and ten months. Its registered office is in Lucknow, Uttar Pradesh, India.

The Company is engaged in the Pharma Industry.

The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.40 Cr.

The company currently has active open charges totaling ₹114.56 Cr. The company has closed loans amounting to ₹72.50 Cr, as per Ministry of Corporate Affairs (MCA) records.

Ranjeet Singh, Angad Singh, and Gurjeet Kaur serve as directors at the Company.

Company Details

  • Location

    Lucknow, Uttar Pradesh, India

  • Telephone

    +91-XXXXXXXXXX

  • Email Address

  • Website

    eugenicsmedi.com

  • Social Media
    -

Corporate Identity Details

  • CIN/LLPIN

    U24232UP2006PTC031683

  • Company No.

    031683

  • Company Classification

    Private Limited Indian Non-Government Company

  • Incorporation Date

    24 Apr 2006

  • Date of AGM

    30 Sep 2023

  • Date of Balance Sheet

    31 Mar 2023

  • Listing Status

    Unlisted

  • ROC Code

    Roc Kanpur

Industry

Pharma

Who are the key members and board of directors at Eugenics Medi Sciences?

Executive Team (1)

NameDesignationAppointment DateStatus
Ranjeet Singh Country flag representing In Managing Director24-Apr-2006Current

Board Members (2)

NameDesignationAppointment DateStatus
Angad Singh Country flag representing In Director 01-May-2017Current
Gurjeet Kaur Country flag representing In Director 24-Apr-2006Current

Financial Performance of Eugenics Medi Sciences.

Eugenics Medi Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 34.77% increase. The company also saw a substantial improvement in profitability, with a 50.07% increase in profit. The company's net worth Soared by an impressive increase of 25.87%.

Graph illustrating revenue growth over time
Graph showing profit and loss trends over time
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023)YOY Growth
(FY 2022)(FY 2021)(FY 2020)(FY 2019)
Total Revenue
34.77%
Revenue from Operations
34.77%
Total Assets
59.92%
Profit or Loss
50.07%
Net Worth
25.87%
EBITDA
44.38%

What is the Ownership and Shareholding Structure of Eugenics Medi Sciences?

In 2023, Eugenics Medi Sciences had a promoter holding of 93.63% and a public holding of 6.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Indicator graph

Charges (Loans)

Open Charges

₹114.56 Cr

Satisfied Charges

₹72.50 Cr

Charges Breakdown by Lending Institutions

  • Axis Bank Limited : 79.50 Cr
  • Others : 18.15 Cr
  • Tata Capital Financial Services Limited : 15.00 Cr
  • Hdfc Bank Limited : 1.14 Cr
  • Pnb Housing Finance Limited : 0.76 Cr

Latest Charge Details

DateLenderAmountStatus
25 Sep 2022Axis Bank Limited₹79.50 CrOpen
29 Jan 2022Hdfc Bank Limited₹1.14 CrOpen
14 Sep 2021Tata Capital Financial Services Limited₹4.00 CrOpen
04 Nov 2020Tata Capital Financial Services Limited₹5.00 CrOpen
03 Nov 2020Others₹18.15 CrOpen

How Many Employees Work at Eugenics Medi Sciences?

Eugenics Medi Sciences has a workforce of 802 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Graph showing employee growth trends

Deals i

Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Eugenics Medi Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eugenics Medi Sciences's trajectory.

Rating

Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts

Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Latest Updates, News, and FAQs on Eugenics Medi Sciences

Recent activity within the organization

  • Charges

    A charge registered on 02 Feb 2019 via Charge ID 100239157 with Hdfc Bank Limited was fully satisfied on 28 Mar 2024.

    28 Mar 2024

  • Charges

    A charge registered on 19 Apr 2022 via Charge ID 100567377 with Tata Capital Financial Services Limited was fully satisfied on 23 Feb 2024.

    23 Feb 2024

  • Charges

    A charge registered on 13 Sep 2021 via Charge ID 100495283 with Tata Capital Financial Services Limited was fully satisfied on 23 Feb 2024.

    23 Feb 2024

  • Charges

    A charge registered on 09 Mar 2012 via Charge ID 10342978 with Tata Capital Financial Services Limited was fully satisfied on 23 Feb 2024.

    23 Feb 2024

  • Charges

    A charge with Others of Rs. 18.15 Cr registered on 03 Nov 2020 with Charge ID 100389606 was modified on 21 Feb 2024.

    21 Feb 2024

  • Annual General Meeting

    Eugenics Medi Sciences Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.

    30 Sep 2023

Frequently asked questions

  • Eugenics Medi Sciences Private Limited was incorporated on 24 Apr 2006.

  • The authorized share capital of Eugenics Medi Sciences Private Limited is ₹ 2.50 Cr and paid-up capital is ₹ 2.40 Cr.

  • Currently 3 directors are associated with Eugenics Medi Sciences Private Limited.

    • Ranjeet Singh
    • Angad Singh
    • Gurjeet Kaur
  • As per Ministry of Corporate Affairs (Mca), the registered address of Eugenics Medi Sciences Private Limited is 101-C Govinda Building1-A Shahnajaf Road Lucknow, Uttar Pradesh, India.

  • The corporate identification number (CIN) of Eugenics Medi Sciences Private Limited is U24232UP2006PTC031683 and the company number is 031683 as per Ministry of Corporate Affairs (MCA).

  • The Official website of Eugenics Medi Sciences Private Limited is https://www.eugenicsmedi.com

  • According to the financial reports for the fiscal year 2023, the revenue trend for Eugenics Medi Sciences Private Limited has risen by 34.77%.

  • As Per 2023 financial reports, 802 employees are currently employed by Eugenics Medi Sciences Private Limited.

  • The financial reports for the fiscal year 2023 indicates that The net worth of Eugenics Medi Sciences Private Limited has experienced an upsurge of 25.87%.

  • As per the financial statements for fiscal Year 2023, The total open charges for Eugenics Medi Sciences Private Limited amount to ₹ 114.56 Cr.

  • The most recent Balance Sheet for Eugenics Medi Sciences Private Limited was filed with the ROC on 31 Mar 2023.